Literature DB >> 23175624

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

M Ghielmini1, U Vitolo, E Kimby, S Montoto, J Walewski, M Pfreundschuh, M Federico, P Hoskin, C McNamara, F Caligaris-Cappio, S Stilgenbauer, R Marcus, M Trneny, P Dreger, E Montserrat, M Dreyling.   

Abstract

To complete the existing treatment guidelines for all tumor types, ESMO organizes consensus conferences to better clarify open issues in each disease. In this setting, a consensus conference on the management of lymphoma was held on 18 June 2011 in Lugano, immediately after the end of the 11th International Conference on Malignant Lymphoma. The consensus conference convened ∼45 experts from all around Europe and selected six lymphoma entities to be addressed; for each of them three to five open questions were to be discussed by the experts. For each question, a recommendation should be given by the panel, supported by the strength of the recommendation based on the level of evidence. This consensus report focuses on the three most common lymphoproliferative malignancies: diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. A second report will concentrate on mantle cell lymphoma, marginal zone lymphoma and T-cell lymphomas.

Entities:  

Mesh:

Year:  2012        PMID: 23175624      PMCID: PMC6267877          DOI: 10.1093/annonc/mds517

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  105 in total

1.  Disease-specific complications of chronic lymphocytic leukemia.

Authors:  Claire Dearden
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

2.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

3.  Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  B Eichhorst; M Dreyling; T Robak; E Montserrat; M Hallek
Journal:  Ann Oncol       Date:  2011-09       Impact factor: 32.976

4.  Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).

Authors:  Dolores Caballero; Jose A García-Marco; Rodrigo Martino; Victoria Mateos; José M Ribera; José Sarrá; Angel León; Guillermo Sanz; Javier de la Serna; Rafael Cabrera; Marcos González; Jorge Sierra; Jesús San Miguel
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

5.  TP53 mutation and survival in chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Barbara Eichhorst; Raymonde Busch; Tina Denzel; Sonja Häbe; Dirk Winkler; Andreas Bühler; Jennifer Edelmann; Manuela Bergmann; Georg Hopfinger; Manfred Hensel; Michael Hallek; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

6.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Authors:  Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

Review 7.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

8.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.

Authors:  Abdulwahab J Al-Tourah; Karamjit K Gill; Mukesh Chhanabhai; Paul J Hoskins; Richard J Klasa; Kerry J Savage; Laurie H Sehn; Tamara N Shenkier; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

10.  Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.

Authors:  Kirsty J Thomson; Emma C Morris; Adrian Bloor; Gordon Cook; Don Milligan; Anne Parker; Fiona Clark; Lynny Yung; David C Linch; Ronjon Chakraverty; Karl S Peggs; Stephen Mackinnon
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

View more
  57 in total

Review 1.  [Current treatment strategies for follicular lymphoma].

Authors:  W Hiddemann; E Hoster; C Schmidt; M Dreyling; M Unterhalt
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

2.  Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?

Authors:  F Buchegger; J-P Mach; O W Press; A Bischof Delaloye; S M Larson; J O Prior; N Ketterer
Journal:  Ann Oncol       Date:  2013-05-23       Impact factor: 32.976

3.  Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Authors:  L Bento; A Boumendil; H Finel; S Le Gouill; S Amorim; H Monjanel; R Bouabdallah; J O Bay; E Nicolas-Virelizier; G McQuaker; G Rossi; R Johnson; A Huynh; P Ceballos; A Rambaldi; E Bachy; R Malladi; K Orchard; D Pohlreich; H Tilly; F Bonifazi; X Poiré; F Guilhot; A Haenel; C Crawley; B Metzner; J Gribben; N H Russell; G Damaj; K Thomson; P Dreger; S Montoto
Journal:  Bone Marrow Transplant       Date:  2017-05-22       Impact factor: 5.483

Review 4.  Rethinking clinical response and outcome assessment in a biologic age.

Authors:  Bruce D Cheson
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

Review 5.  How we manage follicular lymphoma.

Authors:  W Hiddemann; B D Cheson
Journal:  Leukemia       Date:  2014-02-28       Impact factor: 11.528

Review 6.  Management of chronic lymphocytic leukemia.

Authors:  Paolo Ghia; Michael Hallek
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

7.  Utility of quantitative FDG-PET/CT for the detection of bone marrow involvement in follicular lymphoma: a histopathological correlation study.

Authors:  Hugo J A Adams; Thomas C Kwee; Rob Fijnheer; Stefan V Dubois; Peter E Blase; Rutger A J Nievelstein; John M H de Klerk
Journal:  Skeletal Radiol       Date:  2014-06-06       Impact factor: 2.199

Review 8.  Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

Review 9.  Unmet needs in the first-line treatment of follicular lymphoma.

Authors:  C Casulo; L Nastoupil; N H Fowler; J W Friedberg; C R Flowers
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

10.  Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Authors:  Ulrich Jaeger; Marek Trneny; Helen Melzer; Michael Praxmarer; Weerasak Nawarawong; Dina Ben Yehuda; David Goldstein; Bilijana Mihaljevic; Osman Ilhan; Veronika Ballova; Michael Hedenus; Liang-Tsai Hsiao; Wing-Yan Au; Sonja Burgstaller; Gerhard Weidinger; Felix Keil; Christian Dittrich; Cathrin Skrabs; Anton Klingler; Andreas Chott; Michael A Fridrik; Richard Greil
Journal:  Haematologica       Date:  2015-04-24       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.